Clarus Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Clarus Therapeutics Holdings announced its participation in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 20, 2021, at 2:05 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Clarus Therapeutics Holdings announced its participation in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 20, 2021, at 2:05 p.m. ET. The virtual presentation will be accessible via the Investors section of its website, with an archived version available for 90 days post-event. Clarus focuses on advancing androgen and metabolic therapies for both men and women, and its first product, JATENZO®, targets unmet medical needs. For further details, visit Clarus Therapeutics’ official website.
Details
News Market Reaction – CRXT
The recorded move for CRXT in the trading session of this news was -1.20%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NORTHBROOK, Ill., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a specialty pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, Monday, September 20, 2021, 2:05 p.m. ET.
The presentation will be webcast live and can be accessed through the Investors section of Clarus Therapeutics’ website at Investors.ClarusTherapeutics.com. An archived version of the webcast will be available approximately two hours following the live presentation for 90 days.
About Clarus Therapeutics Holdings, Inc.
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women – including potential therapies for orphan indications. Clarus Therapeutics’ first commercial product is JATENZO®. For more information, visit www.clarustherapeutics.com and www.jatenzo.com. Follow us on Twitter (@Clarus_Thera) and LinkedIn (Clarus Therapeutics).
Clarus Investor Relations Contact:
Kara Stancell
kstancell@clarustherapeutics.com
(847) 562-4300 x 206
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.